Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims in the provided content closely match the supplied prescribing-information excerpts (indications, prednisone schedules, empty-stomach instruction, radium Ra 223 warning, hypokalemia/fluid retention monitoring, embryo-fetal toxicity, hypoglycemia with specific antidiabetics, hepatic impairment restriction, strong CYP3A4 inducer dose-frequency adjustment, and food increases exposure). However, the content does not include/quote the full exact label text for every section and therefore cannot be fully validated for completeness (e.g., boxed warnings/contraindications explicitly).
Category Scores
Accurate Statements
Abiraterone acetate tablets are indicated in combination with prednisone for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.
SECTION 1 — INDICATIONS AND USAGE
For metastatic castration-resistant prostate cancer, abiraterone acetate is dosed with prednisone 5 mg twice daily.
SECTION 2.1 — Recommended Dose for Metastatic CRPC
For metastatic high-risk castration-sensitive prostate cancer, abiraterone acetate is dosed with prednisone 5 mg once daily.
SECTION 2.2 — Recommended Dose for Metastatic High-risk CSPC
Abiraterone acetate must be taken on an empty stomach (no food 2 hours before and 1 hour after dosing).
SECTION 2.3 — Important Administration Instructions
Abiraterone acetate plus prednisone/prednisolone is not recommended in combination with radium Ra 223 dichloride outside of clinical trials.
SECTION 5.4 — Increased Fractures and Mortality in Combination with Radium Ra 223 Dichloride
Abiraterone acetate may cause hypokalemia and fluid retention (mineralocorticoid excess) and requires monitoring.
SECTION 5.1 — Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions due to Mineralocorticoid Excess
Abiraterone acetate can cause embryo-fetal toxicity and loss of pregnancy.
SECTION 5.5 — Embryo-Fetal Toxicity (and referenced in SECTION 8.1)
Severe hypoglycemia has been reported when abiraterone acetate is administered to patients with pre-existing diabetes receiving thiazolidinediones (including pioglitazone) or repaglinide.
SECTION 5.6 — Hypoglycemia
Avoid use in patients with baseline severe hepatic impairment (Child-Pugh Class C).
SECTION 2.4 — Hepatic Impairment; also cross-referenced in SECTION 8.6
Avoid concomitant strong CYP3A4 inducers; if a strong CYP3A4 inducer must be co-administered, increase abiraterone dosing frequency to twice daily during co-administration.
SECTION 2.5 — Dose Modification Guidelines for Strong CYP3A4 Inducers
Administration with food increases abiraterone systemic exposure compared with overnight fasting.
SECTION 12.3 — Pharmacokinetics
Unsupported Statements
“The provided FDA-approved labeling excerpts explicitly discuss...” (broad characterization).
This is generally consistent with the supplied excerpts but is not a specific safety/dosing claim; completeness of every relevant label section cannot be verified from the provided content alone.
Contradictions
Important Omissions
Boxed warning assessment, and explicit coverage of contraindications/‘none’ statement, were not directly evaluated against the label (the provided content focuses on other sections).
Importance:
Moderate
Monitoring guidance for hepatotoxicity (ALT/AST and bilirubin thresholds, and related interruption/discontinuation steps) and adrenal insufficiency monitoring were not asserted in the evaluated claims (only referenced generally in the AI narrative).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated, specific claims that were made are supported by the supplied label excerpts and do not present direct contraindications or dosing contradictions. Main gaps relate to completeness of evaluated safety monitoring/warning content rather than incorrect statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete explicit evaluation of certain label elements (e.g., boxed warnings/contraindications and specific hepatotoxicity/adrenal insufficiency monitoring steps).
Suggested Improvement
When auditing, explicitly compare and score each requested label area (boxed warnings, contraindications, full monitoring thresholds for hepatotoxicity/adrenal insufficiency, and any QT/Torsades details) against the provided exact label text/version.